 MyPhuong Le
Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fructose | 10 | 2018 | 132 | 1.760 |
Why?
| | Fructokinases | 6 | 2017 | 42 | 1.260 |
Why?
| | Uric Acid | 9 | 2017 | 167 | 0.770 |
Why?
| | Sweetening Agents | 4 | 2015 | 56 | 0.560 |
Why?
| | Phytochemicals | 1 | 2016 | 13 | 0.480 |
Why?
| | Hypertriglyceridemia | 1 | 2016 | 44 | 0.470 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 821 | 0.390 |
Why?
| | Glucose Transporter Type 5 | 1 | 2013 | 4 | 0.390 |
Why?
| | Glucose Transporter Type 2 | 1 | 2013 | 16 | 0.380 |
Why?
| | Metabolism | 1 | 2011 | 44 | 0.350 |
Why?
| | Sucrose | 1 | 2011 | 115 | 0.340 |
Why?
| | Liver | 3 | 2018 | 1895 | 0.330 |
Why?
| | Metabolic Syndrome | 5 | 2015 | 355 | 0.300 |
Why?
| | Hyperuricemia | 3 | 2015 | 47 | 0.280 |
Why?
| | Glucose Transport Proteins, Facilitative | 1 | 2008 | 16 | 0.280 |
Why?
| | Hypertension | 2 | 2015 | 1273 | 0.270 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2013 | 2146 | 0.260 |
Why?
| | Hemodynamics | 1 | 2011 | 1116 | 0.240 |
Why?
| | Biological Availability | 2 | 2018 | 144 | 0.220 |
Why?
| | Area Under Curve | 2 | 2018 | 329 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2355 | 0.210 |
Why?
| | Beverages | 2 | 2015 | 68 | 0.190 |
Why?
| | Dietary Sucrose | 2 | 2013 | 50 | 0.170 |
Why?
| | Fatty Liver | 3 | 2013 | 254 | 0.160 |
Why?
| | Glucose | 2 | 2018 | 1039 | 0.150 |
Why?
| | Hep G2 Cells | 2 | 2016 | 75 | 0.140 |
Why?
| | Half-Life | 1 | 2018 | 153 | 0.140 |
Why?
| | Kidney | 2 | 2017 | 1498 | 0.130 |
Why?
| | Rats, Wistar | 1 | 2018 | 449 | 0.130 |
Why?
| | Luteolin | 1 | 2017 | 4 | 0.130 |
Why?
| | Garcinia mangostana | 1 | 2016 | 1 | 0.120 |
Why?
| | Angelica archangelica | 1 | 2016 | 1 | 0.120 |
Why?
| | Petroselinum | 1 | 2016 | 2 | 0.120 |
Why?
| | ROC Curve | 1 | 2018 | 619 | 0.120 |
Why?
| | Administration, Oral | 1 | 2018 | 863 | 0.120 |
Why?
| | Diabetes Mellitus | 3 | 2015 | 1076 | 0.110 |
Why?
| | Blood Glucose | 2 | 2018 | 2330 | 0.110 |
Why?
| | Obesity | 3 | 2015 | 3076 | 0.110 |
Why?
| | Plant Extracts | 1 | 2016 | 188 | 0.110 |
Why?
| | Rats | 3 | 2018 | 5581 | 0.100 |
Why?
| | Dehydration | 1 | 2013 | 59 | 0.100 |
Why?
| | Insulin | 2 | 2016 | 2506 | 0.100 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 675 | 0.090 |
Why?
| | Oxidative Stress | 2 | 2017 | 1350 | 0.090 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 265 | 0.090 |
Why?
| | Triglycerides | 2 | 2011 | 518 | 0.090 |
Why?
| | Demography | 1 | 2013 | 287 | 0.090 |
Why?
| | Hepatocytes | 1 | 2012 | 224 | 0.090 |
Why?
| | Kidney Diseases | 1 | 2015 | 427 | 0.080 |
Why?
| | Single-Blind Method | 1 | 2011 | 319 | 0.080 |
Why?
| | Lactic Acid | 1 | 2011 | 306 | 0.080 |
Why?
| | Animals | 9 | 2018 | 38141 | 0.080 |
Why?
| | Indians, North American | 1 | 2015 | 600 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 848 | 0.070 |
Why?
| | Cross-Over Studies | 1 | 2011 | 607 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2017 | 873 | 0.070 |
Why?
| | Male | 8 | 2018 | 72817 | 0.070 |
Why?
| | Dietary Carbohydrates | 1 | 2009 | 147 | 0.070 |
Why?
| | Blood Pressure | 2 | 2013 | 1782 | 0.070 |
Why?
| | Gout | 1 | 2008 | 35 | 0.070 |
Why?
| | Heart Rate | 1 | 2011 | 859 | 0.070 |
Why?
| | Kidney Tubules, Proximal | 1 | 2008 | 130 | 0.070 |
Why?
| | Aldehyde Reductase | 2 | 2017 | 27 | 0.060 |
Why?
| | Phenotype | 1 | 2013 | 3157 | 0.050 |
Why?
| | Humans | 10 | 2017 | 145491 | 0.050 |
Why?
| | Homeostasis | 1 | 2008 | 639 | 0.050 |
Why?
| | Algorithms | 1 | 2011 | 1855 | 0.050 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2015 | 663 | 0.050 |
Why?
| | Mice, Knockout | 3 | 2017 | 3125 | 0.050 |
Why?
| | Sex Factors | 1 | 2008 | 2110 | 0.040 |
Why?
| | Risk Factors | 3 | 2015 | 10874 | 0.040 |
Why?
| | Female | 4 | 2013 | 78763 | 0.040 |
Why?
| | Middle Aged | 2 | 2013 | 36176 | 0.040 |
Why?
| | Mice, Inbred C57BL | 3 | 2017 | 5989 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2582 | 0.040 |
Why?
| | Energy Intake | 2 | 2013 | 506 | 0.030 |
Why?
| | Protective Agents | 1 | 2017 | 42 | 0.030 |
Why?
| | Feeding Behavior | 2 | 2013 | 694 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2012 | 2526 | 0.030 |
Why?
| | Young Adult | 1 | 2011 | 14192 | 0.030 |
Why?
| | Kidney Cortex | 1 | 2013 | 27 | 0.030 |
Why?
| | Food Preferences | 1 | 2015 | 126 | 0.030 |
Why?
| | Ischemia | 1 | 2017 | 430 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4559 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2012 | 26 | 0.020 |
Why?
| | Allopurinol | 1 | 2012 | 70 | 0.020 |
Why?
| | Adolescent | 1 | 2011 | 22485 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2823 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 297 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2012 | 372 | 0.020 |
Why?
| | Weight Gain | 1 | 2013 | 557 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 848 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 45 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2009 | 112 | 0.020 |
Why?
| | Diet, Diabetic | 1 | 2008 | 33 | 0.020 |
Why?
| | Adult | 1 | 2011 | 40707 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2008 | 171 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2012 | 932 | 0.010 |
Why?
| | Mice | 2 | 2013 | 18338 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2013 | 1244 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 738 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1212 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2185 | 0.010 |
Why?
|
|
Le's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|